DrugPatentWatch Database Preview

Details for Patent: 7,309,707

« Back to Dashboard

Which drugs does patent 7,309,707 protect, and when does it expire?

Patent 7,309,707 protects SPIRIVA and is included in one NDA.

Protection for SPIRIVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-seven patent family members in thirty-six countries.

Summary for Patent: 7,309,707

Title:	Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
Abstract:	The invention relates to a crystalline micronisate of (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-7-[(hydroxydi-2-thienylacetyl- )oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0.sup.2,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.
Inventor(s):	Bender; Helmut (Wiesbaden, DE), Graebner; Hagen (Ingelheim, DE), Schindler; Konrad (Ingelheim, DE), Trunk; Michael (Ingelheim, DE), Walz; Michael (Bingen, DE)
Assignee:	Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, DE)
Application Number:	10/385,175
Patent Claim Types: see list of patent claims	Formulation; Compound; Process; Device;

Drugs Protected by US Patent 7,309,707

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Boehringer Ingelheim	SPIRIVA	tiotropium bromide	POWDER;INHALATION	021395-001	Jan 30, 2004		RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: 7,309,707

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	102 12 264	Mar 20, 2002

Non-Orange Book US Patents Family Members for Patent 7,309,707

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,642,268	Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament

International Family Members for US Patent 7,309,707

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Poland	220730
Poland	371799
Peru	08382003
New Zealand	535808